相似文献
1
Chloroquine retinopathy: is there a safe daily dose?
Ann Rheum Dis. 1982 Feb;41(1):52-8. doi: 10.1136/ard.41.1.52.
2
Delayed onset chloroquine retinopathy: case report.
Ann Ophthalmol. 1978 Jun;10(6):723-6.
3
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Ophthalmology. 2016 Jun;123(6):1386-94. doi: 10.1016/j.ophtha.2016.01.058. Epub 2016 Mar 16.
4
[Chloroquine retinopathy: preventable by monitoring the maximum daily dose].
Hautarzt. 1988 Jun;39(6):341-2.
5
RETINOPATHY DURING CHLOROQUINE THERAPY.
Br J Ophthalmol. 1961 Nov;45(11):756-8. doi: 10.1136/bjo.45.11.756.
6
[Ophthalmologic screening history and vision-targeted health status of patients suffering from chloroquine maculopathy].
Ophthalmologe. 2013 Jul;110(7):654-62. doi: 10.1007/s00347-012-2657-1.
7
The blood-retinal barrier in chloroquine retinopathy.
Invest Ophthalmol Vis Sci. 1989 Aug;30(8):1726-31.
8
[Chloroquine retinopathy].
Ophthalmologica. 1972;165(2):81-99. doi: 10.1159/000308474.
9
Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity.
J Rheumatol. 1985 Aug;12(4):692-4.
10
[Severe chloroquine- and hydroxychloroquine-induced retinopathy].
J Fr Ophtalmol. 2006 Jun;29(6):642-50. doi: 10.1016/s0181-5512(06)73825-6.
引用本文的文献
1
Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19.
Natl Sci Rev. 2020 May 28;7(9):1428-1436. doi: 10.1093/nsr/nwaa113. eCollection 2020 Sep.
2
Potential specific therapies in COVID-19.
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620926853. doi: 10.1177/1753466620926853.
3
Macular edema might be a rare presentation of hydroxychloroquine-induced retinal toxicity.
Taiwan J Ophthalmol. 2017 Jan-Mar;7(1):56-58. doi: 10.4103/tjo.tjo_26_17.
4
The effect of oral acetazolamide on cystoid macular edema in hydroxychloroquine retinopathy: a case report.
BMC Ophthalmol. 2017 Jul 12;17(1):124. doi: 10.1186/s12886-017-0517-0.
5
Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration?
Clin Rheumatol. 2007 Aug;26(8):1248-53. doi: 10.1007/s10067-006-0478-9. Epub 2007 Jan 31.
6
Clinically important ocular reactions to systemic drug therapy.
Drug Saf. 1993 Sep;9(3):196-211. doi: 10.2165/00002018-199309030-00005.
7
Report on chloroquine and dapsone in the treatment of rheumatoid arthritis: a 6-month comparative study.
Ann Rheum Dis. 1984 Apr;43(2):200-4. doi: 10.1136/ard.43.2.200.
8
Screening for antimalarial maculopathy in rheumatology clinics.
Br Med J (Clin Res Ed). 1985 Sep 21;291(6498):782-5. doi: 10.1136/bmj.291.6498.782.
本文引用的文献
1
OCULAR LESIONS AFTER TREATMENT WITH CHLOROQUINE.
Br J Ophthalmol. 1961 Apr;45(4):284-97. doi: 10.1136/bjo.45.4.284.
2
Studies of the eye in old age; hole in the macula; a clinicopathologic study.
Am J Ophthalmol. 1950 Feb;33(2):243-7, illust. doi: 10.1016/0002-9394(50)90843-9.
3
Electroretinographic examinations following the application of chloroquine.
Acta Ophthalmol Suppl. 1962;Suppl 70:245-51. doi: 10.1111/j.1755-3768.1962.tb00327.x.
4
Bilateral macular degeneration associated with chloroquine therapy.
Am J Ophthalmol. 1962 Sep;54:381-5. doi: 10.1016/0002-9394(62)93754-6.
5
Two cases of chloroquine-induced retinal damage.
Br Med J. 1962 Mar 31;1(5282):918-9. doi: 10.1136/bmj.1.5282.918.
6
Chloroquine retinopathy.
Am J Ophthalmol. 1962 May;53:769-74. doi: 10.1016/0002-9394(62)93396-2.
7
Electroretinographic changes in chloroquine therapy.
Acta Ophthalmol Suppl. 1962;Suppl 70:252-7. doi: 10.1111/j.1755-3768.1962.tb00328.x.
8
Retinopathy following chloroquine therapy.
Lancet. 1959 Oct 3;2(7101):478-80. doi: 10.1016/s0140-6736(59)90604-x.
9
OCULAR COMPLICATIONS OF CHLOROQUINE THERAPY.
Can Med Assoc J. 1965 Mar 6;92(10):508-13.
10
COMING CATASTROPHES WITH CHLOROQUINE?
Ann Intern Med. 1964 Dec;61:1203-5. doi: 10.7326/0003-4819-61-6-1203.
Zotero 插件